Literature DB >> 6312386

Malignant mixed mesodermal tumors and carcinosarcoma of the ovary: report of eight cases and review of literature.

P Hanjani, R O Petersen, S E Lipton, S A Nolte.   

Abstract

Eight cases of malignant mixed mesodermal tumors and carcinosarcoma of the ovary from our files and 193 cases from the literature were reviewed. An attempt is made to analyze these cases in regard to clinical feature, treatment results, and their outcome. A detailed review of the histogenesis is presented. These tumors grow very rapidly and are usually in advanced stages when diagnosed. Most patients are postmenopausal. Surgery, radiation therapy, and chemotherapy, either alone or in combination, have been used to treat this neoplasm, but 77.6 per cent of the patients are dead of their disease within 1 year. Limited data suggests that patients treated with surgery and combination chemotherapy survive longer. However, further investigation in finding new combination therapy is desired.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6312386     DOI: 10.1097/00006254-198309000-00002

Source DB:  PubMed          Journal:  Obstet Gynecol Surv        ISSN: 0029-7828            Impact factor:   2.347


  4 in total

1.  Cytogenetic, morphologic and oncogene analysis of a cell line derived from a heterologous mixed mullerian tumor of the ovary.

Authors:  J L Becker; P R Papenhausen; R H Widen
Journal:  In Vitro Cell Dev Biol Anim       Date:  1997-05       Impact factor: 2.416

2.  Histogenesis of ovarian malignant mixed mesodermal tumours.

Authors:  T J Clarke
Journal:  J Clin Pathol       Date:  1990-04       Impact factor: 3.411

Review 3.  Chemotherapy and/or radiotherapy in combination with surgery for ovarian carcinosarcoma.

Authors:  T S Shylasree; Andrew Bryant; Ram Athavale
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

4.  Carcinosarcoma of the ovary.

Authors:  M A Harris; L M Delap; P S Sengupta; P M Wilkinson; R S Welch; R Swindell; J H Shanks; G Wilson; R J Slade; K Reynolds; G C Jayson
Journal:  Br J Cancer       Date:  2003-03-10       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.